News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

More than 50 percent of the owners confirm subscription commitments in PledPharma’s planned rights issue

November 14, 2014

PledPharma AB
Company Announcement

More than 50 percent of the owners confirm subscription commitments in
PledPharma’s planned rights issue

Stockholm, 2014-11-14 12:45 CET (GLOBE NEWSWIRE) -- 
At 1 PM today the Extraordinary General Meeting of PledPharma will be held
regarding the Board's proposal to authorize the Board to decide on a rights
issue. Shareholders representing 52.5% of the ownership in PledPharma have
committed to subscribe for their shareholdings in the planned rights issue. The
intension is  that the rights issue will be carried out before the New Year. 

"We are pleased that we have received such a positive response from our
shareholders, and that we have already received subscription commitments
covering more than 50% of the planned rights issue," said CEO Jacques Näsström. 

As previously announced, PledPharma has, during the year, developed a new drug
candidate based on the PLED-platform projected to have significant commercial
potential. The drug candidate, that has recently been named Aladote™, is aimed
at reducing or preventing acute liver failure as a result of acetaminophen
(paracetamol) overdosing, one of the most common poisonings. The problems with
an overdose of acetaminophen are considerable worldwide. In Sweden, the number
of questions regarding acetaminophen poisoning to the poison control center
increased threefold since 2000. In the US overdose of acetaminophen is behind
approximately 78,000 emergency room visits, 33,000 hospitalizations and
numerous deaths annually. 

The background to the planned rights issue is primarily to secure enough
capital to take Aladote™ through a Phase II study up to a licensing deal. The
company also plans to use a smaller portion of the proceeds for running costs,
follow-up of patients in the PLIANT study and business development activities
relating to PledOx®, with the goal of maximizing shareholder value. 


Financial advisors to PledPharma in connection with the planned rights issue
are Pareto Securities AB, which also acts issuing agent in connection with the
rights issue. 

For further information please contact:

Jacques Näsström, CEO PledPharma, tel 073 713 09 79

Michaela Gertz, CFO PledPharma, tel 070 926 17 75

About PledPharma

PledPharma is a Swedish pharmaceutical company developing novel therapies for
life-threatening diseases. The company's initial goal is to develop a drug,
PledOx®, which reduces the serious side effects associated with chemotherapy.
In the latest project PP-100, Aladote™ and its ability to reduce or prevent the
development of acute liver failure due to paracetamol poisoning is evaluated.
Project PP-099 is based on limiting the damage that occurs to the heart muscle
when a patient suffers from acute myocardial infarction. The company has the
potential to offer patients valuable and unique treatments for severe,
life-threatening diseases for which there may be an opportunity for faster
registration process of the drug in the United States called "Breakthrough
therapy". The value of the current market for preventing and reducing serious
side effects from chemotherapy amounts according to Datamonitor to
approximately SEK 70 billion. PledPharma (STO: PLED) is listed on the Nasdaq
First North. Erik Penser AB is Certified Adviser. For more information, see



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10